Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and ...

ModeX Therapeutics Inc., an OPKO Health company, announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. to discover and develop multispecific ...

Regeneron Pharmaceuticals has announced a strategic collaboration with ModeX Therapeutics, a subsidiary of OPKO Health, to develop multispecific antibody treatments designed to target multiple disease ...

(RTTNews) - Wednesday, Regeneron Pharmaceuticals, Inc. (REGN) and ModeX Therapeutics Inc., an OPKO Health company (OPK) entered into a license and collaboration agreement to discover and develop ...

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

School’s out. Teens are bored. And the siren call of social media and video games beckons. Parents and caregivers bungling through new summer routines, or lack thereof, have long sought to balance the ...

WESTON, Mass. - ModeX Therapeutics Inc., a subsidiary of OPKO Health (NASDAQ:OPK), has established a Scientific Advisory Board to guide the development of its immunology and oncology portfolio, which ...

The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as impaired immunological memory development. MDX-2004 is a trispecific ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

ModeX Therapeutics Inc., an OPKO Health, Inc. company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development ...

ModeX Therapeutics, a subsidiary of Opko Health, recently appointed Dr. Giovanni Abbadessa as Chief Medical Officer, bringing over 20 years of experience to the role. Opko Health also completed the ...